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ABSTRACT
INTRODUCTION: To date, more than 120 million working-age Americans have had
COVID-19 infection. Up to 80% of those infected have reported substantial persistent
symptoms, known as long COVID. While current research continues to investigate longterm health effects of COVID-19 infections, less information exists on COVID-19’s
impact on employment and return-to-work status. This study aims to better characterize
the issues related to return-to-work status in those with long COVID.
METHODS: Participants were recruited form the Yale Post-COVID-19 clinic. A mixedmethods survey was administered to collect demographic and employment information.
Standardized scales were utilized to assess symptoms and functional status. Survey
responses were entered into a Qualtrics database and analyzed using SAS software.
RESULTS: Thirty-one participants have been enrolled to-date with a variety of job
categories. Twenty-one respondents (67%) had returned to work in some capacity. The
mean length of time away from work for those who had returned to work was 3 months,
while the mean time for those who had not returned to work was 16 months. Ninety
percent of participants who did not return to work had less than a college degree and
50% had a decreased DLCO. Half of those who had not returned to work were
healthcare workers. Fifty-two percent of participants thought their COVID-19 infection
was work-related, but only 50% of those individuals applied for Workers’ Compensation.
CONCLUSION: In this selected group of workers with history of COVID-19 infection and
persistent symptoms, two thirds of employees had returned to work, but the average
number of lost workdays was substantial. Given the millions of U.S. workers
experiencing persistent symptoms following COVID-19 infection, there is a need to
better understand the impact of COVID-19 on workers, including risk factors for
prolonged sick leave and unemployment, and how to improve work outcomes.
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INTRODUCTION
More than 120 million working-age Americans have been infected with COVID-19
since the spring of 2020 (3). The first reported case of COVID-19 in the US was in midFebruary 2020 (1). Connecticut had its first confirmed case in mid-March 2020 and was
at the center of the first wave of COVID-19 cases in the United States (2) (see Figures 2
and 3). Connecticut experienced its second wave during the fall of 2020 resulting in
further hospitalizations and disability. To date, there have been more than 760,000
cases of COVID-19 in Connecticut, resulting in almost 11,000 deaths (4). Connecticut
had a working population of approximately 1.9 million individuals when COVID-19 first
arrived in the state, and has resulted in significant loss of work hours and disability (5).
The long-term health and socioeconomic consequences of COVID-19 remain uncertain.
Acute COVID-19 Disease
COVID-19 is the illness caused by the novel severe acute respiratory syndrome
coronavirus 2 (SARS CoV-2). Acute COVID-19 infection can result in a wide range of
disease severity. It has been reported that up to 30% of COVID-19 cases may be
asymptomatic (6). Typically, symptomatic COVID-19 initially presents with fever and dry
cough (7). Disease severity is typically mild in about 80% of cases and does not require
hospitalization (8). More severe disease is characterized typically by pneumonia with
bilateral patchy infiltrates on chest imaging and hypoxia, which commonly requires
oxygen supplementation. Up to twenty percent of patients who are hospitalized with
COVID-19 pneumonia develop severe acute respiratory distress syndrome (ARDS),
requiring ICU-level care including mechanical ventilation (7, 9). Risk for severe disease
includes older age, male sex, obesity, and lower socioeconomic status (10-13). Almost
two thirds of adults hospitalized with COVID-19 have been aged 45 years or older (14).
Since the introduction of COVID-19 vaccines in early 2021, the morbidity and mortality
5

of COVID-19 has been reduced among those vaccinated (15, 16), but there has
continued to be disease spread (2).
Long COVID
While most individuals improve over the course of weeks following COVID-19
infection, an entity has been described where individuals have had symptoms persist for
months following acute illness. It was reported that 85% of ICU patients experienced
fatigue 6 months following initial infection (17). Known as Post-Acute Sequelae of Sars
CoV-2 (PASC), this condition has been called informally long COVID. While initially
described in patients with more severe COVID-19 disease, long COVID also occurs
after mild cases of COVID-19 infection. Previous studies have concentrated mostly on
populations who were previously hospitalized and have measured persistent symptoms
and overall quality of life outcomes (18). A wide range of symptoms, from mild to
debilitating, has been described in long COVID, and have been reported to persist for
months after initial COVID-19 infection (19). The most common symptoms are fatigue,
shortness of breath and neurocognitive dysfunction—often described as brain fog.
Literature suggests that anywhere from one quarter to more than 80% of those infected
with COVID-19 may develop persistent symptoms beyond their initial acute infections
(20, 21). There is a phenotype of long COVID with objective findings including fibrosis
following severe COVID-19 pneumonia (22). There are also reports of postural
orthostatic tachycardia (POTS) that can persist for months after acute infection (23).
While some individuals have abnormalities noted on exam and diagnostic testing, the
majority of those with long COVID symptoms have normal medical evaluations and
laboratory testing (24).
Limited prior studies have described the work status of individuals who were
employed at the time of their COVID-19 infection. These studies have focused primarily
6

on hospitalized patients outside the United States. Several studies have shown that
approximately 50% to 80% of patients return to work between 3 to 6 months after their
illness, depending on the study population (18, 24-26). One Danish study showed that
those with worse disease courses, such as ICU-level care, were less likely to return to
work by six months following illness (27). Several studies in health care workers have
shown that persistent symptoms are common, but most of these workers have been
able to return to work (28, 29).

Context of Study:
Few studies have looked at the impact of COVID-19 on workers across different
industry sectors, the duration of time away from work, ability to return to work,
accommodations needed, and type of work-related benefits. This pilot study serves as
an opportunity to identify important issues faced by workers with COVID-19 who have
persistent symptoms.
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Methods:
This study was approved by the Yale University Institutional Review Board (study
#2000030952). Participants were recruited for this pilot observational study from the
panel of patients who had been evaluated at the Yale Winchester Center for Lung
Disease Post COVID-19 Recovery Program (RECOVERY). Briefly, individuals are
referred to this clinic from the community for persistent COVID-19 infections or following
hospitalizations. Less than half of participants in this clinic have been hospitalized. This
multidisciplinary clinic evaluates patients utilizing pulmonary function tests (PFTs),
baseline labs, a standardized shortness of breath scale and a PROMIS Global-10
evaluation for patient-perceived global health. Not all patients are referred for imaging or
invasive testing. The RECOVERY clinic has enrolled approximately 900 participants to
date (30). Participants were asked if they were willing to participate in the study
following their evaluation at RECOVERY clinic. The average time from symptom onset
to survey enrollment was approximately sixteen months (495 days). Inclusion criteria
included those who have already been referred to the RECOVERY clinic, adults 18
years of age or older, English speakers, and individuals who were employed at the time
of their COVID-19 infections. Fifty-one participants were approached and asked to
participate in the study. Twenty patients were unable to schedule telephone interviews
to complete the survey. Verbal consent was obtained either in-person or over the
phone. Thirty-one participants have been recruited to date. See Figure 1 for an
approximate timeline of events related to recruiting.
A mixed methods survey was administered to collect demographic information,
employment information such as job title and industry, whether COVID-19 was thought
to be work-related, current work status, duration of time off work for COVID-19, job
modifications and employment benefits. Standardized scales were utilized to assess
8

symptoms. This included the Modified Medical Research Council dyspnea scale
(mMRC) (31), Cognitive Failures Questionnaire (CFQ) (32) and the PROMIS Global-10
questionnaire (33). Chart review was performed to confirm COVID-19 diagnosis, and
the timing and severity of illness. Additional information available from respondents’
clinic visits included pulmonary function tests, PROMIS Global-10 survey and mMRC
dyspnea scale obtained at the time of initial RECOVERY clinic visit. Data was entered
into a Qualtrics database.
Data was analyzed using SAS software (34). Data analysis was primarily
descriptive in nature. For analysis of symptoms, Fisher Exact T tests were utilized given
the limited number of participants. Qualitative answers were reviewed from the
interviews and discussed in a descriptive nature.
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Results:
To date, 31 participants have enrolled in the study. Table 1 presents a summary
of the study population characteristics. The study population is predominantly female
(84%). The mean age of participants was 48.2 years. The population is predominantly
white (77%) and non-Hispanic (74%). Most of the respondents owned a home at the
time of their COVID-19 infection (68%). Regarding pre-existing health conditions, more
than half of study participants were obese (52%), four (13%) had hypertension, three
(10%) had Diabetes Mellitus II, and 2 (7%) had a pre-existing lung disease.
Table 2 presents a summary of employment characteristics for participants at the
time of their initial COVID-19 infections. These characteristics are further summarized
by return-to-work status. Participants were employed in a variety of job sectors,
including healthcare (32%), education (29%), management (26%),
transportation/production (7%), and self-employed (7%). Healthcare positions included
medical support staff, nurses, direct care staff and one MD. The differences between
job sectors and return-to-work status are visualized in Figure 2. Twenty-nine percent of
respondents had a total household income between $50,000 and $100,000 per year,
while 26% made less than $50,000. Fifteen percent made more than $100,000 per year
and 26% either did not know their household income or preferred not to say. For
statistical analysis, education was dichotomized to two distinct levels; those with a
college degree or more and those with a high school diploma or associate degree or
some college. Fifty-two percent of the participants had a college degree or more, while
48% had a high school diploma, associate degree or some college. Of those individuals
that had not returned to work, only 10% had a college degree or more, while those that
did return to work, 71% had a college degree or more. This difference was statistically
significant (p=0.0024).
10

At the time of their initial COVID-19 infection 77% of the respondents were
employed full time, 74% reported having employer-sponsored health insurance, 23%
reported receiving health insurance from another source (either the state or through a
spouse) and only one respondent did not have health insurance at the time of their
initial infection. The benefit differences among those who did and did not return to work
were not statistically significant.
Table 3 describes the general clinical course of participants’ COVID-19
infections. Most respondents were not hospitalized (81%) during their initial COVID-19
infection. Of those that were hospitalized (n=6), 3 were admitted to the ICU, two of
whom were intubated. Lung function test results at the time that participants were
enrolled in the study are summarized. Nineteen percent of participants had a reduction
in FEV1 of < 80%, and 21% of participants had a reduction in DLCO of < 70%.
As shown in Table 3, the mean number of days from COVID-19 infection to first
visit at the Yale Post COVID-19 Recovery clinic was 249 days (about 8 months). The
mean number of days from initial clinic date to participation in study interview was 230
days (about 8 months). In total, approximately 16 months passed from time of infection
to study enrollment. Sixty-eight percent of participants had returned to work by the time
of interview, while 10 respondents (32%) had not returned to work in any capacity, two
of whom had attempted to return, but had to stop work shortly after returning (<2 weeks)
due to severe symptoms. For the purposes of this study, this group is categorized as
having not returned to work. Of the respondents who had returned to work, the mean
number of days out of work from time of infection to first day back was 93.9 (about 3
months). Individuals who had not returned to work had been away from work for a mean
of 495 days (almost 17 months). Approximately half of the participants (52%) believed
that they had a COVID-19 infection that was most likely obtained at work.
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Table 4 summarizes clinical characteristics, lung function testing and symptoms
of participants at the time of the study interview for all participants, comparing those
who returned to work and those who did not. Half of the participants who did not return
to work had a DLCO <70%, while only one participant who did return to work had a
DLCO <70%. This difference was statistically significant (p=0.0105).
The number of days from first symptoms to survey was a mean of 471 days
(approximately 16 months) and was similar for both those who had and had not
returned to work. Almost all respondents reported that they still had symptoms at the
time of the interview. The most prevalent symptom was fatigue (84%), followed by
shortness of breath (74%), and neurocognitive symptoms including brain fog (65%).
Differences between those who had and had not returned to work were not significant.
The mMRC dyspnea scale asks participants to self-rate their shortness of breath from 0
to 4, 0 being shortness of breath only with strenuous exercise, and 4 being too short of
breath to leave the house. Participants averaged a score of 1.7, which was not
statistically significant between those who have and have not returned to work.
PROMIS Global-10 questionnaire was administered at study enrollment. The
mean global physical score was 8.9 (approximate T-score in the 32 nd percentile) and the
mean global mental score was 11.6 (approximate T-score in the 43 rd percentile).
Notably, on the PROMIS Global-10 question regarding fatigue, 38% of respondents
noted that their fatigue was severe or very severe. Baseline PROMIS Global-10 scores
were also obtained at the time of initial RECOVERY clinic visit (data not shown). These
scores were not significantly different despite the approximate 8 months between
RECOVERY survey and interview survey, demonstrating the chronicity of reported
symptoms.
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The Cognitive Failures Questionnaire was administered at the time of interview,
which asked questions regarding concentration, memory, and attentiveness, with high
scores indicating a higher level of cognitive dysfunction, with a score of 50 being about
average (32). Participants scored slightly below the average (39.8), and there were no
statistical differences between those who had and had not returned to work.
Table 5 illustrates the work readiness of those who were able to return to work.
Of the individuals who had returned to work, only 19% reported that they felt ready to
return, and almost half (43%) had received formal accommodations. Accommodations
included light duty, fewer hours, remote work or altered schedule. Most individuals
(67%) still reported formal accommodations at the time of interview. Of the provided
responses, 87% worried that they would not return to their baseline prior to their
COVID-19 infection.
A summary of the utilization of benefits for individuals in the study population is
shown in Table 6. Individuals were asked if they had applied for any disability benefits
during their time off. Over a third had applied for disability (39%), either short term or
long term. Of those who had applied, 83% had received some form of disability benefit,
the remaining of which were pending. Of those that responded that their COVID-19
infection was work-related, only half have applied for Workers’ Compensation. As of this
writing, only 2 cases have been accepted, 1 was denied, and 5 were still pending.
Notably 25% of those who had work-related COVID-19 infections reported that they
were advised by their employers to not apply for Workers’ Compensation.
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Discussion:
Several findings in this pilot study exploring work outcomes in employees with
long COVID are notable. While all but one participant had health insurance, about a
third (36%) reported not having any paid leave benefit as part of their employment at the
time of their COVID-19 infection. Although only 19% were hospitalized, persistent
symptoms were common over a year after their acute COVID-19 illness, especially
fatigue (85%), shortness of breath (74%), and memory problems (65%). Despite these
on-going symptoms, two-thirds of participants were able to return to work. However,
they were away from work for an average of over 3 months and 90% remained
concerned that they would not return to their baseline.
Of note, a third of participants have been unable to return to work, and their
mean time out of work is 16 months. Those unable to return to work were more likely to
have a reduced DLCO on their pulmonary function testing, were more likely to be a
healthcare worker and were less likely to have a college degree or higher. A number of
clinical, job and personal characteristics were not associated with post-COVID work
status, including the severity of the acute illness, severity of symptoms or job benefits.
Also notable, 50% of participants thought that their COVID-19 infection was most
likely work-related, although only half of these participants applied for Workers’
Compensation, and to-date, over a year after their COVID-19 illness, only 25% who
applied have had their claim accepted.
The findings of this study are generally consistent with the limited studies to date
evaluating work status and determinants of return-to-work ability following COVID-19
infection. Previous studies have shown that persistent symptoms are common
anywhere from 3 to 6 months following initial COVID-19 illness (9, 18, 35). This study
further demonstrates that symptoms of long COVID can persist up to 16 months after
14

initial infection, with no significant improvement noted from the time of initial evaluation
in the post COVID recovery program to interview for this study, a mean of 8 months.
Previous long COVID studies have explored return-to-work status as an outcome
following COVID-19 infection, with around 80% of individuals returning to work (26). A
large Danish study found that up to 98% had returned to work after six months following
their COVID-19 infection (27), however, the study was conducted using a Danish
population which may not be characteristic of the US population. Furthermore, the study
lacked a distinction among specific job categories. Early in the pandemic there had
been studies specifically exploring the relationship of healthcare workers returning to
work after COVID-19 infection (28, 36, 37), which showed that most health care workers
are able to return to work despite on-going symptoms. Studies that explore return-towork issues in employees outside of the healthcare field are very limited. The findings
presented here describe the impact of long COVID on workers from a number of
different job sectors.
The use of standardized questionnaires for individuals with COVID-19 infection
enables comparison across studies. In a cross-sectional study of all individuals
presenting to the Cleveland Clinic during the COVID-19 pandemic, PROMIS-10
questionnaires were administered showing a PROMIS-10 Global Physical T-score of
48.5 and a PROMIS-10 Global Mental T-score of 45.8 (38). The results of our study are
lower for both Global Mental and Global Physical T scores, 32 and 43 respectively,
showing lower physical and mental health, and also no improvement in scores over
time. This difference may be due to the fact that the Cleveland Clinic study did not limit
participants to those with COVID-19 infection, but also included non-COVID patients
presenting during the pandemic, and also did not select for patients with long COVID.
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Previous studies have looked at mMRC scores in COVID-19-infected
populations. One such study showed that those with lower oxygen saturations, likely
with worse COVID-19 pneumonia, experienced greater shortness of breath (higher
mMRC scores) on questionnaire. (39). Our study results were not significantly different
for those who had and had not returned to work.
The Cognitive Failures Questionnaire has been used in previous studies to
measure attention and distractibility. The original studies validating the CFQ indicated
that the mean score was 34 to 55 depending on specific sample population (32). The
mean of 39 found in our study indicates that respondents had a score that was about
average in reported general populations. To the best of our knowledge, there have
been no studies to evaluate the use of the CFQ in COVID-19.
The findings of this study are also consistent with previous literature discussing
how there is a subset of patients who have decreased lung function after COVID-19
infection, particularly in those with severe COVID-19 illness (18, 26) and that these
patients have more trouble returning to work.
This pilot study found that although the many individuals with long COVID were
able to return to work, there is still a significant number of individuals who have been
unable to return. The individuals in this study population represent a group that was
primarily infected within the first year of the COVID-19 pandemic, and despite this
almost a third have still not been able to return to work. The majority of respondents in
this study were not severely ill during their initial infection but have had symptoms
persist for more than 16 months. Healthcare workers were more likely to not return to
work. This may be partly due to their inability to have accommodations at work,
including the nature of their in-person work that cannot be done remotely. It is notable
that of those that did apply for a disability benefits, most did receive it in some form after
16

their initial infection. Also notable, those who did not return to work did have a more
significant decrease in their DLCO. Employees felt as though their infections were workrelated, though many did not apply for Workers’ Compensation.
Individuals with less than a college education were more likely to have not
returned to work. This reflects that jobs requiring less education may be more physical
in nature. More manual jobs may have less flexibility to accommodate such offerings as
remote work, modified scheduling, or adjusted work duties.
One strength of this study is that we are looking at a US population of workers
who had relatively mild disease, which is the case for most people who contract COVID19 infection, which makes it more generalizable to the larger number of people who
have had relatively mild disease. Another strength is the length of time between initial
COVID-19 infection and study involvement. As noted, many studies have looked at
individuals only a few months after their COVID-19 infections, but this study indicates
that symptoms are lasting much longer and may continue to persist for years after
COVID-19 infection.
There are several important limitations of this study. One is that this is a selective
sample of patients from a group that had been referred to a post-COVID-19 recovery
program. These individuals, by definition, do not represent a typical COVID-19 patient.
Despite being a self-selected group of individuals within a long COVID-19 clinic, a
significant proportion were still able to return to work. The number of those that returned
to work may be partly explained by the extended time between initial infection and the
interview. Another limitation of this pilot study is the small sample size. There did not
appear to be a statistically significant association with symptoms or occupation category
and return-to-work status, but there are trends that can be noted. By recruiting a larger
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sample, it may be possible to gain greater insight into the characteristics that affect the
ability to return to work.
Given that we will continue to deal with COVID-19 infections in the future, we will
likely see an increasing number of individuals suffering from long COVID, resulting in
loss of work and disability. Although this is a pilot study, it may be used to direct future
research in the field. More work needs to be done to identify risk factors for inability to
return to work and interventions that can help workers who want to return to work do so.
Further research needs to address why individuals with lower education may be less
likely to return to work. There is also a need to better educate workers about their rights
regarding accommodations and benefits.
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Figures and tables:

Figure 1. COVID-19 Infections in Connecticut & Timeline of Study
Jan 2020: First COVID-19
case reported in the US

March 2021 to March 2022:
29/31 participants have been
infected with COVID-19 during
this period (red line)

March 2020: First COVID19 infection reported in CT

Early Winter 2021:
Vaccines become
available

April 2020: Yale PASC
RECOVERY clinic
begins seeing patients

October 2021 through
April 2022: Study
enrollment

Figure 1 displays the total number of COVID-19 positive cases (Y-axis) in Connecticut from mid-March 2020 through April 2022 (Xaxis). Superimposed, is a general timeline of COVID-19 in CT and this study. The mean number of days from initial COVID-19
infection to first encounter with the Yale PASC RECOVERY clinic was 249 days, or approximately 8 months. The mean time from
initial COVID-19 infection to time of interview for this study was 479 days, or approximately 16 months. Data (1), Figure source (2).
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Table 1. Demographics
Demographic characteristics
N=31
Age (years), mean ± SD
Sex
Female
Male
Race
White
African American or Black
American Indian
Other
Education
High School Grad/GED
Some College or Associate
College Graduate
More Than College
Housing Status
Own
Rent
Smoking Status
Never
Former
Current
Pre-existing conditions
BMI >30kg/m2
Hypertension
Diabetes
Prior Lung disease

n (%)
48.2 ± 13.8
26 (83.9)
5 (16.1)
24 (77.4)
3 (9.7)
1 (3.2)
3 (9.6)
6 (19.4)
9 (29.0)
5 (16.1)
11 (35.5)
21 (67.7)
10 (12.3)
23 (74.2)
7 (22.6)
1 (3.33)
16 (51.6)
4 (12.9)
3 (9.7)
2 (6.6)

Table 1 consists of baseline demographics for the study population.
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Table 2. Employment Characteristics
Employment descriptors
N=31
Type of work
Healthcare
Education
Management
Transport/Production
Self-employed
Household Income
<$50,000
$50,000-$100,000
>$100,000
Don’t know/Prefer not to say
Education
College Degree or More
Associate Degree or Some College
Self-Reported Time Working
Full-Time
Part-Time
Health Insurance
Employer sponsored insurance
Other health insurance source
None
Paid Leave offered by employer
Yes (Sick/Vacation or other)
None

Total
N=31

Returned to
work
N=21

Have not
returned
N=10

10 (32.3)
9 (29.0)
8 (25.8)
2 (6.5)
2 (6.5)

5 (23.8)
7 (33.3)
7 (33.3)
2 (9.5)
0 (0.0)

5 (50.0)
2 (20.0)
1 (10.0)
0 (0.0)
2 (20.0)

8 (25.8)
9 (29.0)
6 (15.4)
8 (25.8)

5 (23.8)
1 (4.8)
10 (47.6)
5 (23.8)

3 (30.0)
0 (0.0)
4 (40.0)
3 (30.0)

16 (51.6)
15 (48.4)

15 (71.4)*
6 (28.6)*

1 (10.0)*
9 (90.0)*

24 (77.4)
7 (22.6)

18 (85.7)
3 (14.3)

6 (60.0)
4 (40.0)

23 (74.2)
7 (22.6)
1 (3.3)

17 (81.0)
4 (19.0)
0 (0.0)

6 (60.0)
3 (30.0)
1 (10.0)

20 (64.5)
11 (35.5)

13 (61.9)
8 (38.1)

7 (70.0)
3 (30.0)

Table 2 is a summary of employment characteristics of the study population at the time of their initial COVID-19
infection.
*Education was dichotomized and differences were measured using Fisher Exact T test which was significant
with a p= 0.0024.
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Table 3. Clinical Course
Illness characteristics
N=31
Severity of Illness
Not Hospitalized
Hospitalized
Highest level of care (n=7)
Medical Floor
ICU
Most Recent PFTs
FEV1 <80%
DLCO <70% (n=29)
Both FEV1 <80% and DLCO <70%
Duration, mean ± SD
Days from infection to Yale PASC clinic
Days from infection to study enrollment
Returned to work?
Yes
No
Days out of work, mean ± SD
Those who have returned to work
Have not returned to work

n (%)
25 (80.6)
6 (19.4)
3 (43.0)
3 (43.0)
6 (19.4)
6 (20.7)
3 (9.7)
249 ± 148
479 ± 162
21 (67.7)
10 (32.3)
93.9 ± 118
495 ± 188

Do you believe your COVID-19 was work related?
Yes
No

16 (51.6)
15 (48.4)

Table 3 describes the clinical course for participants. Two participants did not have DLCOs
obtained on PFTs
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Table 4. Characteristics at Time of Interview
Clinical characteristics
Age, Mean ± SD
Sex
Female
Male
Days from symptom onset to study
interview
Symptoms at time of Interview
Shortness of breath
Fatigue
Memory/Neurocognitive
Palpitations
Chest pain
mMRC dyspnea scale
(0 to 4 scale), mean ± SD
SOB score
PROMIS Global-10 (4 to 20)
Post Global Physical
Post Global Mental
Cognitive Failure Questionnaire
(0 to 100)
DLCO <70% (n=29)
FEV1 < 80%
Worry you will not return to
baseline? (n=30)
Agree
Disagree

Total
N=31
48.2 ± 13.8

Returned to
work
N=21
46.7 ± 15.4

Have not
returned
N=10
51.3 ± 9.53

26 (83.9)
5 (16.1)

17(81.0)
4 (19.0)

9 (90.0)
1 (10.0)

479 ± 162

471 ± 152

495 ± 188

23 (74.1)
26 (83.9)
20 (64.5)
11 (35.4)
11 (35.4)

16 (76.2)
16 (76.2)
14 (66.7)
7 (33.3)
6 (28.6)

7 (70.0)
10 (100.0)
6 (60.0)
4 (40.0)
5 (50.0)

1.7 ± 1.1

1.6 ± 1.2

1.9 ± 09

8.9 ± 2.3
11.6 ± 2.9

9.5 ± 2.2
12.0 ± 2.2

7.7 ± 2.1
10.7 ± 4.1

39.8 ± 18.9
6 (20.7)*
6 (19.4)

38.7 ± 19.2
1 (5.3)*
3 (14.3)

41.9 ± 19.2
5 (50.0)*
3 (30.0)

26 (86.7)
4 (13.3)

18 (90.0)
2 (10.0)

8 (80.0)
2 (20.0)

Table 4 characterizes the clinical characteristics, lung function and symptoms at the time of
study enrollment.
*Fisher Exact two-sided T test was preformed and was significant at p=0.0105
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Figure 2. Return-To-Work Status
Figure 2 displays those who
have and have not returned
to work based on job sector

12
10
8
6
4
2
0

Have Returned

Have Not Returned

Table 5. Work Readiness For Those That Returned
Work characteristics
N=21
Did you feel ready to return to work?
Yes
No
Did you receive accommodations?
Yes
No
Do you still have accommodations? (n=9)
Yes
No

n (%)
4 (19.0)
17 (81.0)
9 (42.9)
12 (57.1)
6 (66.7)
3 (33.3)

Individuals were asked about how they felt about returning to work.
Accommodations consisted of reduced hours, different job duties, and remote work
options.
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Table 6. Work-Related Benefits
Specific benefit inquiries
Applied for Disability?
Yes
No
Disability Status? (n=12)
Received
Pending

Do you believe your COVID-19 was work
related?
Yes
No
Applied for Workers’ Compensation? (n=16)
Yes
Status of Workers’ Compensation case? (n=8)
Accepted
Denied
Pending/unsure

Total
N=31

Returned to
work
N=21

Have Not
returned
N=10

12 (38.7)
19 (61.3)

6 (28.6)
15 (71.4)

6 (60.0)
4 (40.0)

10 (83.3)
2 (16.7)

6 (100.0)
0 (0)

4 (66.7)
2 (33.3)

16 (51.6)
15 (48.4)

10 (47.6)
11 (52.4)

6 (60.0)
4 (40.0)

8 (50.0)

4 (40.0`)

4 (66.6)

2 (25.0)
1 (12.5)
5 (62.5)

1 (25.0)
1 (25.0)
2 (50.0)

1 (25.0)
0 (0.0)
3 (75.0)

Table 6 characterizes work-related benefits in both those who have and have not returned to work. Individuals were asked
where they most likely were infected with COVID-19.
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